IRIS PubliCatt

Coratti, Giorgia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.270
EU - Europa 2.135
AS - Asia 824
AF - Africa 25
SA - Sud America 24
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 5.286
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.225
IT - Italia 764
SE - Svezia 498
SG - Singapore 353
IE - Irlanda 244
CN - Cina 189
DE - Germania 134
ID - Indonesia 113
FR - Francia 109
RU - Federazione Russa 75
GB - Regno Unito 61
FI - Finlandia 46
IN - India 45
CA - Canada 30
BE - Belgio 25
IR - Iran 23
CZ - Repubblica Ceca 22
TR - Turchia 22
UA - Ucraina 21
ES - Italia 20
CH - Svizzera 18
NL - Olanda 15
CI - Costa d'Avorio 14
RO - Romania 14
HK - Hong Kong 13
JP - Giappone 13
MK - Macedonia 12
BR - Brasile 11
PA - Panama 11
PH - Filippine 11
RS - Serbia 11
IL - Israele 10
KR - Corea 10
PL - Polonia 10
EG - Egitto 9
LT - Lituania 7
AT - Austria 6
PT - Portogallo 6
AR - Argentina 5
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
CO - Colombia 3
DK - Danimarca 3
MX - Messico 3
MY - Malesia 3
PE - Perù 3
PK - Pakistan 3
SK - Slovacchia (Repubblica Slovacca) 3
AU - Australia 2
BT - Bhutan 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
NZ - Nuova Zelanda 2
ZA - Sudafrica 2
AL - Albania 1
BD - Bangladesh 1
BG - Bulgaria 1
CL - Cile 1
EE - Estonia 1
GL - Groenlandia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
QA - Qatar 1
SA - Arabia Saudita 1
TH - Thailandia 1
TW - Taiwan 1
VN - Vietnam 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.286
Salva come PNG Salva come JPEG
Città #
Chandler 588
Ashburn 322
Singapore 278
Dublin 215
New York 165
Rome 161
Milan 125
Jakarta 113
Marseille 64
Princeton 58
San Mateo 56
Boston 53
Moscow 46
Los Angeles 33
Wilmington 33
Helsinki 31
Bremen 28
Palermo 28
Chicago 27
Nanjing 25
Ann Arbor 22
Beijing 22
Munich 22
Dearborn 21
Brussels 20
London 20
Boardman 19
Brno 18
Fairfield 18
Pune 18
Toronto 17
Houston 15
Kish 15
Abidjan 14
Redmond 14
Turin 14
Andover 12
Cattolica 12
Redwood City 12
Washington 12
Menlo Park 11
Paris 11
Seattle 11
Salamanca 10
Skopje 10
Augusta 9
Bologna 9
Busto Arsizio 9
Florence 9
Jinan 9
Lancaster 9
Seoul 9
Bari 8
Falkenstein 8
Lappeenranta 8
Norwalk 8
Ottawa 8
Shanghai 8
São Paulo 8
Woodbridge 8
Cairo 7
Hebei 7
Jacksonville 7
Naples 7
Shenzhen 7
Changsha 6
Frankfurt am Main 6
Hong Kong 6
Leawood 6
Niš 6
Tokyo 6
Amsterdam 5
Genoa 5
Guangzhou 5
Harrisburg 5
Istanbul 5
Jiaxing 5
Lisbon 5
Mountain View 5
Naaldwijk 5
Nanchang 5
San Diego 5
Santa Clara 5
Secaucus 5
Shenyang 5
Stockholm 5
Vienna 5
Wandsworth 5
Ancona 4
Barcelona 4
Bern 4
Bitonto 4
Brindisi 4
Cambridge 4
Fort Worth 4
Giugliano in Campania 4
Krakow 4
Kunming 4
Lawrence 4
Monza 4
Totale 3.170
Salva come PNG Salva come JPEG
Nome #
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 217
Performance of Upper Limb module for Duchenne muscular dystrophy 138
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 110
Revised upper limb module for spinal muscular atrophy: Development of a new module 98
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 88
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 81
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 79
Developmental milestones in type I spinal muscular atrophy 79
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 79
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 78
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 77
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 76
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 76
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 74
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 73
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 70
Developmental milestones in type I spinal muscular atrophy 69
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 69
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 69
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 69
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 69
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 68
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 67
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 66
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 65
Hammersmith Infant Neurological Examination in low-risk infants born very preterm: a longitudinal prospective study 65
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 64
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 63
Assessing floppy infants: a new module 63
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 61
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 61
Longitudinal natural history in young boys with Duchenne muscular dystrophy 60
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 60
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 59
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 59
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 57
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 55
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 54
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 54
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 53
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 53
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 52
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 52
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 52
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 51
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 51
Clinical Variability in Spinal Muscular Atrophy Type III. 51
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 51
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 50
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational study 50
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 49
Development of an academic disease registry for spinal muscular atrophy 48
Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. 47
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 46
Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function. 46
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 45
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 43
Gain and loss of abilities in type II SMA: A 12-month natural history study 43
North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up 43
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 43
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 43
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 43
Revised upper limb module for spinal muscular atrophy: 12 month changes 42
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 41
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 41
Revised upper limb module for spinal muscular atrophy: Development of a new module 40
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 40
Risdiplam in Type 1 Spinal Muscular Atrophy 39
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 39
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 39
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 38
Longitudinal natural history of type I spinal muscular atrophy: A critical review 38
First international workshop on rehabilitation management and clinical outcome measures for spinal muscular atrophy 38
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 37
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 37
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 37
Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy. 37
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 36
Sleep disorders in spinal muscular atrophy 33
Language Development in Preschool Duchenne Muscular Dystrophy Boys 33
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 33
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 30
An observational study of functional abilities in infants, children, and adults with type 1 SMA 30
Development of an International SMA Bulbar Assessment for Inter-professional Administration 30
An observational study of functional abilities in infants, children, and adults with type 1 SMA 29
Language Development in Preschool Duchenne Muscular Dystrophy Boys 29
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 28
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 26
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 26
An observational study of functional abilities in infants, children, and adults with type 1 SMA 23
Long term follow-up of scoliosis progression in type II SMA patients 22
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 22
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 22
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 20
Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study 20
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 18
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 18
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 17
Assessing Prevalence and Characteristics of Oro-bulbar Involvement in Children and Adults with SMA Type 2 and 3 Using a Multimodal Approach 17
Totale 5.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.235
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.235
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020100 0 0 0 0 3 20 16 2 5 8 44 2
2020/202164 1 7 3 3 11 2 4 1 9 7 15 1
2021/2022693 45 7 15 92 52 27 17 95 50 41 122 130
2022/20232.008 179 244 122 269 135 256 143 177 273 37 101 72
2023/20241.655 60 295 70 139 76 293 195 83 42 85 130 187
2024/2025735 64 53 215 197 206 0 0 0 0 0 0 0
Totale 5.429